viewHemoGenyx Pharmaceuticals

Hemogenyx Pharmaceuticals delivers encouraging data on antibody drug candidate

“This antibody should, if successful, provide a new and potentially effective treatment for a form of blood cancer for which adult survival rates are currently very poor," said CEO Vladislav Sandler

test tubes
Researchers are assessing the potential of CDX to treat acute lymphoblastic leukaemia, which affects both children and adults

HemoGenyx Pharmaceuticals PLC (LON:HEMO) shares soared higher on Thursday as its chief executive Vladislav Sandler said the company was encouraged by new data on its antibody drug candidate for use in acute lymphoblastic leukaemia (ALL).

The company has already shown the treatment may have a role in tackling acute myeloid leukaemia.

The latest lab tests revealed the CDX bi-specific antibody was capable of eliminating a subset of ALL cells that contain mixed-lineage leukemia 1 gene rearrangements and that overexpress a protein called FLT3.

The drug developer said CDX binds to the protein that is located on the surface of target cells, binds to the CD3 protein and ultimately redirects t-cells to kill the target cells.

Hemogenyx said it is planning to verify the efficacy of CDX in ALL in an animal model in the near future.

CEO Sandler said the latest data demonstrated the potential to widen the application of its CDX antibody.

New and potentially effective treatment

“We previously demonstrated that CDX antibody may be effective in treating acute myeloid leukaemia, another type of aggressive blood cancer,” he explained.

“This antibody should, if successful, provide a new and potentially effective treatment for a form of blood cancer for which adult survival rates are currently very poor."

ALL is an aggressive form of blood cancer that affects both children and adults.

While the prognosis for paediatric patients is generally good (80-90% survival), the prognosis for patients over 60 years of age remains very poor, with survival rates of only 10-15%.

The value of the market globally, meanwhile, is put at US$1.5bn.

In early morning trading, Hemogenyx shares topped the London market's gainers board, up 30% at 3p.

 -- Adds share price --

Quick facts: HemoGenyx Pharmaceuticals

Price: 6.075 GBX

Market: LSE
Market Cap: £26.77 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of HemoGenyx Pharmaceuticals named herein, including the promotion by the Company of HemoGenyx Pharmaceuticals in any Content on the Site, the...



HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors. It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations...

on 27/6/18

2 min read